Translarna Benefits Don’t ‘Justify the Current Cost’: NICE Draft Guidance
The U.K.’s National Institute for Health and Care Excellence (NICE) has published new draft guidance that does not recommend Translarna (ataluren) be covered to treat Duchenne muscular dystrophy (DMD) caused by nonsense mutations. According to NICE, although there’s evidence Translarna can benefit people with DMD, it’s not worth…